IMCAS 2024: Rion Aesthetics’ CEO, Alisa Lask, to Unveil Cutting-Edge Platelet-Derived Exosome Technology Insights
Alisa Lask, CEO of Rion Aesthetics, with a diverse background in medical devices, pharmaceuticals, and skincare markets, stands at the forefront of revolutionizing the regenerative aesthetics industry. (Photo: Business Wire)
NEWPORT BEACH, Calif. (BUSINESS WIRE)
RION AESTHETICS, a regenerative medicine company pioneering the use of platelet exosomes for skin care and restorative clinical applications, received the prestigious LaunchPad SBDC Judges Award at the 2022 Aesthetics Tech Summit.
“It was an honor to present our groundbreaking technologies to leading physicians, aesthetic experts, investors, and entrepreneurs,” said Alisa Lask, Chief Executive Officer of RION. “We are thrilled to be the first and only Aesthetics company offering platelet-derived exosomes for use in skincare as well as actively developing restorative clinical applications.
Out of 65 Octane LaunchPad SBDC companies only 7 were selected as finalists using objective scoring methodology that has been in practice for 10+ years. This elite group of companies developing innovative aesthetic technologies, unveiled their technologies in front of a panel of independent judges.
“We are proud to recognize future luminaries as they lead Aesthetics into new areas,” said Director of LaunchPad SBDC, Mike Hill. “Octane and LaunchPad SBDC are thrilled to help assist these companies and most importantly amplify their capital funding structure as they enter this Aesthetic beloved space. We look forward to watching RION AESTHETICS in the coming years.”
About RION AESTHETICS
RION AESTHETICS is a regenerative medicine company, pioneering the use of platelet exosomes for skin care and restorative clinical applications. Backed by over 15 years of visionary science, we aim to transform skincare through the introduction of Plated™ SkinScience, leveraging the power of exosomes to address the most persistent skin challenges. Beyond skincare, RION AESTHETICS is pursuing FDA approval for Regenosomes, the first room-temperature stable off-the-shelf regenerative exosome that drives soft tissue healing, with the ability to address unmet needs in aesthetics medicine for applications in hair loss, regenerative tissue fillers, and topical nano-toxin technology.
Contacts
Alisa Lask
alask@rionaesthetics.com
